Shareholders' Equity (Details Textual) - USD ($)						1 Months Ended						12 Months Ended
	May 15, 2018	Sep. 06, 2017	Dec. 28, 2016	May 10, 2016	Dec. 31, 2015	Nov. 30, 2018	Nov. 20, 2018	Nov. 18, 2018	May 31, 2018	Mar. 06, 2018	Nov. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Shareholders' Equity (Textual)
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses														$ 4,099,000
Shares reserved for future issuance (in shares)												1,535,634	1,301,521
Exercise price per share						$ 0.30
Expected term of shares												6 years 1 month 9 days
Sale of stock price per share				$ 0.08
Fixed commission rate												3.00%
Warrants to purchase ordinary shares												16,328,950
Minimum [Member]
Shareholders' Equity (Textual)
Expected term of shares													5 years 3 months 22 days	5 years 3 months 22 days
Equity Exchange Program [Member]
Shareholders' Equity (Textual)
Compensation payment												$ 159,000
Description of equity exchange program		On the Equity Exchange Program’s expiration date of October 4, 2017, 46 holders tendered options to purchase an aggregate of 945,416 ordinary shares, representing 96.4% of all options eligible for exchange, and on October 5, 2017, the Company granted to these holders an aggregate of 251,872 new RSUs. 180,167 of these new RSUs were granted to the Company’s executive officers and “named executive officers”
Canacord Gunuity Inc [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares (in shares)	117,891
RSUs held by non-employee consultants [Member]
Shareholders' Equity (Textual)
RSUs granted (in shares)												89,148
Options granted (in shares)												3,454
ATM Offering Program [Member]
Shareholders' Equity (Textual)
Aggregate offering price				$ 25,000,000								$ 25,000,000
Stock issuance costs under equity distribution agreement as a percent of gross proceeds				3.00%								3.00%
Price per share of shares sold under ATM offering program (in USD per share)												$ 1.09
Issuance of ordinary shares in an ATM offering of ordinary shares, gross of issuance expenses												$ 1,400,000
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses												236,000
Issuance expenses												$ 211,000
Sale of ordinary shares												1,247,172
Proceeds percentage of sale of the ordinary shares				8.00%
Limitation on sales, description												The Company may raise up to $25 million under its ATM Offering Program pursuant to the terms of its agreement with the sales agent. However, due to limitations under the rules of Form S-3, which have applied to the Company since it filed its annual report on Form 10-K, in February 2017, as of the date of this annual report we may only issue up to approximately $13.7 million in primary offerings under our effective registration statement on Form S-3 (the "Form S-3"), including our ATM Offering Program, during any 12-month period while we remain subject to these limitations. Because we have already sold $15.7 million in the ATM Offering Program since its inception, we may only raise up to a remaining $9.3 million using the program, subject to the $13.7 million cap during any rolling 12-month period.
Gross proceeds amount												$ 1,400,000
ATM Offering Program One [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares in an ATM offering of ordinary shares, net of issuance expenses												14,500,000
Issuance expenses												$ 1,171,000
Sale of ordinary shares												7,552,318
Compensation payment												$ 471,000
Gross proceeds												15,700,000
ATM Offering Program One [Member] | Minimum [Member]
Shareholders' Equity (Textual)
Issuance expenses												$ 1,100,000
Follow-on public offering [Member]
Shareholders' Equity (Textual)
Gross proceeds											$ 8,300,000
Additionally issued and sold pre-funded units						26,259,332
Description of follow-on public offering						The Company completed its follow-on public offering in which the Company issued and sold 18,200,498 units, each consisting of one ordinary share and one warrant to purchase one ordinary share. Each unit was sold to the public at a price of $0.30 per unit, additionally the company issued and sold 26,259,332 pre-funded units, each unit was sold to the public at a price of $0.29 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.01 per share and one warrant to purchase one ordinary share. The total gross proceeds received from the follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million. (including proceeds from the exercise of 2,267,284 pre-funded warrants at the closing of the offering).
Additionally issued and sold public price per unit						$ 0.29
Gross proceeds amount						$ 13,100,000
Proceeds from exercise of pre-funded warrants						2,267,284
Additional pre-funded warrants to purchase aggregate ordinary shares exercised												14,061,666
Additional proceeds of pre-funded warrants												$ 140,617,000
Underwriters warrants to purchase ordinary shares issued												2,667,590
Underwriters warrants to purchase exercisable term												November 20, 2018 until November 15, 2023
Underwriters warrants to purchase exercisable price per share												$ 0.375
Warrants to purchase ordinary shares						44,459,830
Underwriting agreement, description											The Company entered into the Underwriting Agreement with National Securities Corporation ("National"), in connection with the Company's follow-on public offering of 6,857,000 ordinary shares. Each ordinary share was sold to the public at a price of $1.05 per share. On November 22, 2017 National exercised in full its option to purchase 1,028,550 additional ordinary shares at the public offering price of $1.05 per share, less the underwriting discount.
Commission expenses											$ 7,200,000
Restricted Stock Units (RSUs) [Member]
Shareholders' Equity (Textual)
Weighted average grant date fair value, restricted stock units (in USD per share)												$ 9.28	$ 1.44	$ 9.28
Weighted average grant date fair value, options (in USD per share)													$ 1.02	$ 4.75
Total intrinsic value of options exercised												$ 340,367,000	$ 29,000	$ 844,000
Share option plan [Member]
Shareholders' Equity (Textual)
Total fair value of shares vested												2,918	3,785	3,626
Award vesting period, description												The options generally vest over four year, with certain options granted to non-employee directors during the fiscal year ended December 31, 2018, vesting over one year.
Shares reserved for future issuance (in shares)													1,301,521
Unrecognized cost of shares												$ 1,900,000
Expected term of shares												2 years
Timwell investment agreement [Member]
Shareholders' Equity (Textual)
Gross proceeds										$ 20,000,000
Fees and other related expenses										705,000
Net aggregate proceeds of after deducting fees and other related expenses										$ 4,300,000
Description of tranche consisting									The Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the closing of the First Tranche of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the closing of the first tranche of the Timwell transaction in May 15, 2018, the Company issued 117,891 ordinary shares to Canaccord Genuity.	The Company entered into an investment agreement with Timwell Corporation Limited, a Hong Kong corporation ("Timwell"), as amended on May 15, 2018 (the "Investment Agreement"), pursuant to which the Company agreed to issue to Timwell, in three different tranches, an aggregate of 16,000,000 ordinary shares in return for aggregate gross proceeds of $20 million. The closing of each tranche is subject to certain closing conditions. The closing of the first tranche (the "First Tranche Closing") took place on May 15, 2018, upon which Timwell received 4,000,000 ordinary shares for an aggregate purchase price of $5,000,000, and Timwell and the Company signed a registration rights agreement in the form attached to the Investment Agreement. The net aggregate proceeds of the First Tranche Closing after deducting fees and other related expenses in the amount of approximately $705 thousands were approximately $4.3 million. The remaining investment is to occur in two tranches, including $10 million for the issuance to Timwell of 8,000,000 ordinary shares (the "Second Tranche") and $5 million for the issuance to Timwell of 4,000,000 ordinary shares (the "Third Tranch"). The closing of the second and third tranches is subject to specified closing conditions, including, with respect to the second tranche, the signing of a license agreement and a supply agreement and the formation of the China JV (the "China JV") based on the JV Framework Agreement, and, with respect to the third tranche, the successful production of certain ReWalk products by the China JV. The second tranche closing was initially expected to occur by July 1, 2018 and the third tranche closing was initially expected to occur by December 31, 2018 and no later than April 1, 2019.
Kreos Capital [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares (in shares)			47,717
Exercise price per share					$ 9.64
Warrants exercisable, description					Currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.
Drawdown amount under loan agreement			$ 8,000,000
Warrants to purchase ordinary shares							167,012
H.C. wainwright [Member] | Follow-on public offering [Member]
Shareholders' Equity (Textual)
Issuance of ordinary shares (in shares)								5,799,108
Sale of stock price per share						$ 0.30
Additionally issued and sold pre-funded units								5,799,108
Additionally issued and sold public price per unit								$ 0.29
Underwriters warrants to purchase ordinary shares issued						12,401,390
Underwriters warrants to purchase exercisable price per share								$ 0.01